This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access TicoVac® (Tick-Borne Encephalitis Vaccine (whole Virus inactivated)) prescribing information and adverse event reporting can be found at the bottom of the page.

TicoVac (Tick-Borne Encephalitis Vaccine (whole Virus inactivated))

Focus on Tick-Borne Encephalitis  (TBE)

Help protect people from TBE with TicoVac and TicoVac Junior1,2

TBE is a rare viral infection of the central nervous system, that affects the brain and spinal cord.3,4 Transmission to humans most commonly occurs through one bite of an infected tick.5

TBE can be serious

TBE is a serious infection that can appear in two stages.

  • The first stage of flu-like symptoms occurs between 2 days and 4 weeks after being bitten by an infected tick.4,6
  • In some people second-stage symptoms occur due to the virus spreading to the central nervous system and causing meningitis or encephalitis.4,6

There is no specific treatment for TBE. Most patients with TBE will recover, but up to one third will suffer long-term complications of the disease.7

The following activities (below), whether they be for leisure or work purposes, could result in people being more likely to come into contact with ticks:6,7

The invisible risk​​​​​​​​​​​​​

Ticks carrying the TBE virus are usually active from early spring to late autumn and are generally found close to the ground in forested or grassy areas, including parks and gardens, as well as meadows.6

TBE endemic countries

You may know that ticks can transmit Lyme disease,7 but are you aware that in certain parts of Europe and Asia, they can also carry TBE?3 Vaccination can help to prevent TBE and  should be considered when travelling to the following countries:5,8,9


  • Albania
  • Austria
  • Belarus
  • Bosnia and Herzegovina
  • Bulgaria
  • Croatia
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Kosovo
  • Latvia
  • Liechtenstein
  • Lithuania
  • Moldova
  • Montenegro
  • Netherlands
  • Norway
  • Poland
  • Romania
  • Russia
  • Serbia
  • Slovakia
  • Slovenia
  • Sweden
  • Switzerland
  • Turkey
  • Ukraine
  • China
  • Japan
  • Kazakhstan
  • Kyrgyztan
  • Mongolia
  • Republic of Korea


  1. TicoVac Summary of Product Characteristics. September 2018.
  2. TicoVac Junior Summary of Product Characteristics. September 2018.
  3. Factsheet about tick-borne encephalitis (TBE). European Centre for Disease Prevention and Control. Available at: (last accessed: March 2021)
  4. Haglund M. and Gunther G. Tick-borne encephalitis--pathogenesis, clinical course and long-term follow-up. Vaccine. 2003;21 Suppl 1:S11-8  
  5. Lindquist L. and Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371(9627):1861-71.
  6. Travel Health Pro. TBE factsheet. Available at: Accessed March 2021.
  7. World Health Organisation Regional Office for Europe. Tick-borne encephalitis in Europe. Available at: Accessed March 2021
  8. WHO. International travel and health. Tick-borne encephalitis. (Last Accessed: March 2021)
  9. Travel Health Pro. Denmark. Available at: Accessed March 2021.
PP-TCV-GBR-0081. March 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020